A Possible Novel Anti-Inflammatory Mechanism for the Pharmacological Prolyl Hydroxylase Inhibitor 3,4-Dihydroxybenzoate: Implications for Use as a Therapeutic for Parkinson’s Disease
Parkinson’s disease (PD) is an age-related neurodegenerative disorder characterized in part by the preferential loss of nigrostriatal dopaminergic neurons. Although the precise etiology of PD is unknown, accumulating evidence suggests that PD involves microglial activation that exerts neurotoxic eff...
Saved in:
Main Authors: | Shankar J. Chinta, Subramanian Rajagopalan, Abirami Ganesan, Julie K. Andersen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Parkinson's Disease |
Online Access: | http://dx.doi.org/10.1155/2012/364684 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis
by: Lei Tian, et al.
Published: (2024-12-01) -
Prolyl 4‐hydroxylase α‐subunit family regulation of type I collagen deposition and IL17RB/c‐Jun activation synergistically mediate choline dehydrogenase promotion of colorectal cancer metastasis
by: Xiaowen Yang, et al.
Published: (2025-01-01) -
Anti-Inflammatory and Neuroprotective Role of Natural Product Securinine in Activated Glial Cells: Implications for Parkinson’s Disease
by: Dmitri Leonoudakis, et al.
Published: (2017-01-01) -
The MSDIN family in amanitin-producing mushrooms and evolution of the prolyl oligopeptidase genes
by: Hong Luo, et al.
Published: (2018-12-01) -
Management of Hypertension and Diabetes in Obesity: Non-Pharmacological Measures
by: Joseph M. Pappachan, et al.
Published: (2011-01-01)